Nora A Fierro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7046369/publications.pdf

Version: 2024-02-01

516215 552369 44 760 16 26 citations h-index g-index papers 44 44 44 1031 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Chapter 3 New Insights on Mast Cell Activation via the High Affinity Receptor for IgE. Advances in Immunology, 2008, 98, 85-120.	1.1	182
2	Genetic, metabolic and environmental factors involved in the development of liver cirrhosis in Mexico. World Journal of Gastroenterology, 2015, 21, 11552.	1.4	48
3	Distribution of HBV genotypes F and H in Mexico and Central America. Antiviral Therapy, 2013, 18, 475-484.	0.6	45
4	Hepatitis E virus: An ancient hidden enemy in Latin America. World Journal of Gastroenterology, 2016, 22, 2271-2283.	1.4	40
5	Immunologic, metabolic and genetic factors in hepatitis C virus infection. World Journal of Gastroenterology, 2014, 20, 3443.	1.4	31
6	COVID-19 and the liver: What do we know after six months of the pandemic?. Annals of Hepatology, 2020, 19, 590-591.	0.6	30
7	Association with Spontaneous Hepatitis C Viral Clearance and Genetic Differentiation of IL28B/IFNL4 Haplotypes in Populations from Mexico. PLoS ONE, 2016, 11, e0146258.	1.1	26
8	High prevalence of occult hepatitis B virus genotype H infection among children with clinical hepatitis in west Mexico. Memorias Do Instituto Oswaldo Cruz, 2014, 109, 728-737.	0.8	25
9	TCR-Dependent Cell Response Is Modulated by the Timing of CD43 Engagement. Journal of Immunology, 2006, 176, 7346-7353.	0.4	24
10	Prevalence of hepatitis A, B and C serological markers in children from western Mexico. Annals of Hepatology, 2012, 11, 194-201.	0.6	24
11	T cell aggregation induced through CD43: intracellular signals and inhibition by the immunomodulatory drug leflunomide. Journal of Leukocyte Biology, 2003, 74, 1083-1093.	1.5	21
12	High prevalence of HBV infection, detection of subgenotypes F1b, A2, and D4, and differential risk factors among Mexican risk populations with low socioeconomic status. Journal of Medical Virology, 2017, 89, 2149-2157.	2.5	21
13	<i>CD36</i> genetic variation, fat intake and liver fibrosis in chronic hepatitis C virus infection. World Journal of Hepatology, 2016, 8, 1067.	0.8	20
14	PKCÎ, is required for the activation of human T lymphocytes induced by CD43 engagement. Biochemical and Biophysical Research Communications, 2004, 325, 133-143.	1.0	19
15	Increase of drug use and genotype 3 in HCV-infected patients from Central West and Northeast Mexico. Annals of Hepatology, 2015, 14, 642-651.	0.6	17
16	Spontaneous hepatitis C viral clearance and hepatitis C chronic infection are associated with distinct cytokine profiles in Mexican patients. Memorias Do Instituto Oswaldo Cruz, 2015, 110, 267-271.	0.8	16
17	Immunometabolic Effect of Cholesterol in Hepatitis C Infection: Implications in Clinical Management and Antiviral Therapy. Annals of Hepatology, 2018, 17, 908-919.	0.6	13
18	CD43 regulates the threshold for T cell activation by targeting Cbl functions. IUBMB Life, 2011, 63, 940-948.	1.5	12

#	Article	IF	CITATIONS
19	Cytokine Expression Profiles Associated With Distinct Clinical Courses In Hepatitis A Virus–Infected Children. Pediatric Infectious Disease Journal, 2012, 31, 870-871.	1.1	11
20	Conjugated bilirubin affects cytokine profiles in hepatitis A virus infection by modulating function of signal transducer and activator of transcription factors. Immunology, 2014, 143, 578-587.	2.0	11
21	Challenges in Management of Hepatitis A Virus Epidemiological Transition in Mexico. Annals of Hepatology, 2019, 18, 14-22.	0.6	11
22	First detection of hepatitis E virus genotype 3 as a common infectious agent in patients with chronic liver damage in Mexico. Annals of Hepatology, 2019, 18, 571-577.	0.6	11
23	T-helper 17-related cytokines and IgE antibodies during hepatitis A virus infection in children. Memorias Do Instituto Oswaldo Cruz, 2015, 110, 263-266.	0.8	10
24	Hepatitis E Virus Genotype 1 and Hepatitis A Virus Dual Infection in Pediatric Patients with a Low Socioeconomic Status from Mexico. Intervirology, 2018, 61, 105-110.	1.2	10
25	Conjugated Bilirubin Upregulates TIM-3 Expression on CD4 ⁺ CD25 ⁺ T Cells: Anti-Inflammatory Implications for Hepatitis A Virus Infection. Viral Immunology, 2018, 31, 223-232.	0.6	8
26	Latin America and chronic diseases: A perfect storm during the COVID-19 pandemic. Annals of Hepatology, 2021, 22, 100332.	0.6	8
27	Rethinking the immune properties of bilirubin in viral hepatitis: from bench to bedside. Clinical and Translational Immunology, 2015, 4, e54.	1.7	7
28	Conjugated Bilirubin Differentially Regulates CD4+ T Effector Cells and T Regulatory Cell Function through Outside-In and Inside-Out Mechanisms: The Effects of HAV Cell Surface Receptor and Intracellular Signaling. Mediators of Inflammation, 2016, 2016, 1-15.	1.4	7
29	Rethinking cytokine function during hepatitis A and hepatitis C infections. Advances in Bioscience and Biotechnology (Print), 2013, 04, 13-18.	0.3	7
30	Increase of drug use and genotype 3 in HCV-infected patients from Central West and Northeast Mexico. Annals of Hepatology, 2015, 14, 642-51.	0.6	7
31	Modeling the Th17 and Tregs Paradigm: Implications for Cancer Immunotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 675099.	1.8	6
32	COVID-19 in Latin America and the caribbean region: Symptoms and morbidities in the epidemiology of infection. Current Opinion in Pharmacology, 2022, 63, 102203.	1.7	6
33	Spatial and Temporal Distribution of Hepatitis A Virus and Hepatitis E Virus Among Children with Acute Hepatitis in Mexico. Viral Immunology, 2021, 34, 653-657.	0.6	5
34	Human immunodeficiency virus and the liver: The impact of coinfection with hepatotropic viruses. Annals of Hepatology, 2019, 18, 285-286.	0.6	4
35	Hepatitis E Virus: Still an Enigma in Mexico. Annals of Hepatology, 2018, 17, 544-546.	0.6	3
36	Evidence for Increased Inflammatory Cytokine Profile in Hepatitis E Virus-Infected Obese Patients: Implications for Chronic Liver Disease. Viral Immunology, 2020, 33, 600-609.	0.6	3

#	Article	IF	CITATIONS
37	COVID-19 and gastrointestinal symptoms in Mexico, a systematic review: does location matter?. BMC Infectious Diseases, 2021, 21, 555.	1.3	3
38	A Comprehensive Meta-Analysis of COVID-19 in Latin America. SOJ Microbiology & Infectious Diseases, 2020, 8, 1-11.	0.7	3
39	Antiretroviral Therapies for Human Immunodeficiency Virus and Liver Disease: Challenges and opportunities. Annals of Hepatology, 2020, 19, 121-122.	0.6	2
40	Is hepatitis A virus infection under control? lessons in the application of viral sequencing for the development of vaccination schemes in emergency situations. EBioMedicine, 2019, 39, 11-12.	2.7	1
41	Challenges in research and management of hepatitis E virus infection in Cuba, Mexico, and Uruguay. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2018, 42, 1-7.	0.6	1
42	Scavenger Receptors in the Pathogenesis of Viral Infections. Viral Immunology, 2022, 35, 175-191.	0.6	1
43	Are previous viral infections important for the COVID-19 outcomes?. Annals of Hepatology, 2021, 25, 100554.	0.6	O
44	Viral Kinetics of an Acute Hepatitis B Virus Subgenotype F1b Infection in a Mexican Subject. Clinical Liver Disease, 2022, 19, 41-48.	1.0	0